Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315517 | 0.86 | KDM1A (0.31) | KDM1A | |
| SCHEMBL26812225 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM1AEPHX2CD274PDCD1LG2 | |
| SCHEMBL27080337 | 0.76 | KDM1A (0.41) | SMN1; SMN2KDM1AEPHX2CD274PDCD1LG2 | |
| SCHEMBL27172421 | 0.76 | CTSK (0.43) | EPHX2 | |
| SCHEMBL24007484 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM1AEPHX2CD274PDCD1LG2 | |
| SCHEMBL19872412 | 0.75 | CD274 (0.41) | SMN1; SMN2KDM1AEPHX2CD274PDCD1LG2 | |
| SCHEMBL26232484 | 0.75 | CHRNB2 (0.43) | SMN1; SMN2EPHX2EPHX1KDM4E | |
| SCHEMBL25543746 | 0.74 | CYP2C19 (0.37) | — | |
| SCHEMBL25624760 | 0.73 | — | — | |
| SCHEMBL25538065 | 0.73 | CRHBP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | SMN1; SMN2 697/4885KDM1A 3015/4885EPHX2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.